{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:37:59Z","timestamp":1780947479881,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.bbrc.2020.02.132","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T18:36:53Z","timestamp":1582828613000},"page":"607-613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comprehensive mutanome analysis of Lewis lung cancer reveals immunogenic neoantigens for therapeutic vaccines"],"prefix":"10.1016","volume":"525","author":[{"given":"Tao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6574-118X","authenticated-orcid":false,"given":"Fengzeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5245-212X","authenticated-orcid":false,"given":"Zichen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-8445","authenticated-orcid":false,"given":"Junqiu","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangwei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6259-915X","authenticated-orcid":false,"given":"Zhiqiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2020.02.132_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-018-0081-4","article-title":"Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?","author":"Recondo","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2020.02.132_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.02.132_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01848","article-title":"Neoantigen targeting - dawn of a new era in cancer immunotherapy?","author":"Wirth","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2020.02.132_bib4","article-title":"Applications of immunogenomics to cancer","author":"Liu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.02.132_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/ni.3682","article-title":"Final common pathway\u2019 of human cancer immunotherapy: targeting random somatic mutations","author":"Tran","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbrc.2020.02.132_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4325874","article-title":"Recent development and clinical application of cancer vaccine: targeting neoantigens","author":"Pan","year":"2018","journal-title":"J.\u00a0Immunol. Res."},{"key":"10.1016\/j.bbrc.2020.02.132_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.02.132_bib8","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.02.132_bib9","article-title":"Global cancer statistics, 2012","author":"Torre","year":"2015","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2020.02.132_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2020.02.132_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial","author":"Butts","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2020.02.132_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2015.07.035","article-title":"A\u00a0phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer","author":"Giaccone","year":"2015","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.bbrc.2020.02.132_bib13","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-0855","article-title":"A\u00a0phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients","author":"Rodriguez","year":"2016","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.bbrc.2020.02.132_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2015.07.004","article-title":"Personalized approaches to active immunotherapy in cancer","author":"Ophir","year":"2016","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.bbrc.2020.02.132_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/bs.ai.2016.01.001","article-title":"The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer","author":"Ward","year":"2016","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.bbrc.2020.02.132_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: an overview of clinical trials","author":"Melero","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2020.02.132_bib17","article-title":"Neoantigens in cancer immunotherapy","volume":"80","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.02.132_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/nm.3773","article-title":"High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma","author":"Linnemann","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2020.02.132_bib19","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"80\u2013","author":"Tran","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.02.132_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","author":"Coulie","year":"2014","journal-title":"Nat. Rev. Canc."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20304137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20304137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:50:02Z","timestamp":1757764202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X20304137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0006291X20304137"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.02.132","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive mutanome analysis of Lewis lung cancer reveals immunogenic neoantigens for therapeutic vaccines","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.02.132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}